FGFR pathway is considered as a therapeutic target—several small molecule inhibitors targeting FGFR receptor tyrosine kinases have been already approved or in clinical trials, both in solid tumors and in hematological malignancies (ClinicalTrials.gov identifier: NCT03011372) [24,25]. The gene discussed is NTRK1; the disease is hematologic disorder.